November 20, 2025

Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data

IntelME Verdict

Leadership Change

TL;DR

Metagenomi and Ovid Therapeutics CEOs step down, Cogent Biosciences sees stock rise on groundbreaking stomach cancer data, Metagenomi restructures for gene-editing program.

Analysis

The CEO transitions at Metagenomi and Ovid Therapeutics signal strategic shifts in focus and operations. Metagenomi's restructuring towards gene-editing for hemophilia A could indicate a pivot towards promising therapeutic areas. For biotech/pharma professionals, these changes may hint at evolving R&D priorities and potential future pipeline advancements.

Source

BioPharma Dive↗